Mateon Therapeutics is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in orphan oncology indications. VTTs include vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA approved and widely used in cancer treatment. These 2 approaches (VDAs and AAs) have distinct yet complementary mechanisms of action.
At Mateon, we believe that we can significantly improve cancer therapy by combining these 2 complementary approaches. When utilized this way, VDAs disrupt existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
We are committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
Company Details
- Founded
- -
- Address
- 701 Gateway Boulevard, Suite 210, South San Francisco,ca 94080,united States
- Phone
- (650) 635-7001
- in****@****eon.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- mateon.com
- Keywords
- IT Consulting.
- HQ
- South San Francisco, CA
Mateon Therapeutics Questions
Mateon Therapeutics's helpline number is (650) 635-7001
Mateon Therapeutics's website is mateon.com
Mateon Therapeutics's LinkedIn profile is https://www.linkedin.com/company/mateon-therapeutics
Mateon Therapeutics's industry is
Biotechnology Research
Mateon Therapeutics's top competitors are
Pebble Life Science,
Oncotelic,
Elaria,
Aiara Inc.,
Capricor Therapeutics, Inc.,
Marina Biotech, Inc.,
Genomictree Inc,
Pointr Data Inc.,
Monopar Therapeutics Inc.,
Lifesciencehistory.com.
Mateon Therapeutics's support email address is info@mateon.com
Mateon Therapeutics's categories are Biotechnology Research
Mateon Therapeutics's founding year is 1996
